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ABSTRACT 
Objectives: Data on the role of tobacco exposure in systemic sclerosis (SSc) severity 
and progression are scarce. We aimed to assess the effects of smoking on the evolution 
of pulmonary and skin manifestations in the EUSTAR database. 
Methods: Adult SSc patients with data on smoking history and a 12-24 months follow-
up visit were included. Associations of severity and progression of organ involvement 
with smoking history and the comprehensive smoking index (CSI) were assessed using 
multivariable regression analyses.  
Results: 3,319 patients were included (age 57 years; 85% female), 66% were never 
smokers; 23% ex-smokers and 11% were current smokers. Current smokers had a 
lower percentage of anti-topoisomerase autoantibodies than previous or never smokers 
(31% vs. 40% and 45%, respectively). 
Never smokers had a higher baseline forced expiratory volume in one second/forced 
vital capacity (FEV1/FVC) ratio than previous and current smokers (p<0.001). The 
FEV1/FVC ratio declined faster in current smokers than in never smokers (p=0.05) or 
ex-smokers (p=0.01).  
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The baseline modified Rodnan skin score (mRSS) and the mRSS decline were 
comparable across smoking groups.  
Although heavy smoking (more than 25 pack years) increased the odds of digital ulcers 
by almost 50%, there was no robust adverse association of smoking with digital ulcer 
development. 
Conclusion: The known adverse effect of smoking on bronchial airways and alveoli is 
also observed in SSc patients; however robust adverse effects of smoking on the 
progression of SSc-specific pulmonary or cutaneous manifestations were not observed. 
 
Systemic sclerosis (SSc) is a rare, multisystem autoimmune disorder [1]. Hypoxia and 
oxidative stress have been implicated in the pathophysiology of its generalized 
microangiopathy and fibrosis [1]. Although smoking does not appear to confer a risk for 
SSc development [2], it has vasoconstrictive effects and increases free radical exposure, 
and together with other proinflammatory and immunomodulatory effects may 
exacerbate SSc manifestations [3]. Data on the role of tobacco exposure with regards to 
the severity of SSc organ manifestations and progression are however scarce and at 
times contradictory [4]. A Canadian cohort study of 606 patients for example reported 
an increased frequency of digital ulcers (DU) in smokers [4], whereas a study of 172 
Australian patients, found no association of smoking history with vascular 
characteristics [5]. 
Larger studies and robust data assessing the possible effect of smoking on SSc 
presentations and importantly SSc progression are lacking. We therefore assessed the 
association of tobacco exposure with the prevalence and evolution of SSc organ 
manifestations. 
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PATIENTS AND METHODS 
This study is based on the multinational, longitudinal European Scleroderma Trials and 
Research (EUSTAR) database [6]. Each center obtained local ethical committee 
approval; each patient provided written informed consent. Data collection started in 
2004. The smoking module, however, was introduced to the database in 2013; hence 
smoking data were only collected from that date onwards. Data for this study were 
exported in May 2017. 
Patients were included if they were older than 18 years, fulfilled the 1980 ACR or 2013 
ACR/EULAR criteria for SSc, and if the smoking status was known; additionally, patients 
were required to have a follow-up visit 12-24 months after baseline. Information about 
the core data collected in EUSTAR can be found elsewhere [6]. The EUSTAR smoking 
module collects patient-reported smoking status (never/previous/current smoker), the 
number of pack-years, and the smoking start and cessation dates.  
The influence of smoking behavior was assessed on several disease parameters: forced 
expiratory volume in one second/forced vital capacity ratio (FEV1/FVC), FVC, single 
breath diffusing capacity for monoxide (DLCO/sb), systolic pulmonary arterial pressure 
as estimated by echocardiography (PAPsys), modified Rodnan skin score (mRSS) and 
digital ulcers (DU). Further information about outcome measures as well as variables 
describing the study population can be found in Supplementary Table 1.  
Outcome progression was downscaled to ‘rate of change per 12 months’ unless 
otherwise stated. 
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Statistical analysis 
Frequencies/percentages or means/standard deviations (SD) were calculated; groups 
were compared using Χ2-tests/Fisher’s exact tests or t-tests/ANOVA. Multiple linear and 
logistic regression analyses were applied to adjust outcome/exposure associations with 
a priori defined potential confounding factors (age, sex, time since the onset of 
Raynaud’s phenomenon [RP] and since the first non-RP manifestation, antibody status, 
and skin involvement). As the SSc specific antibodies might be on the causal pathway 
between smoking and SSc organ involvement we additionally analyzed the data without 
adjustment for antibody status, these results can be found in the supplementary 
(Supplementary Tables 2, 3, 4). 
Three smoking metrics were modelled separately: (Model 1) never/previous/current 
smoking, (Model 2) smoking intensity (pack-years; never smokers = 0 pack-years, light 
smokers = 0-10 pack-years, medium smokers = 10-25 pack-years, heavy smokers = >25 
pack-years), and (Model 3) comprehensive smoking index (CSI). The CSI is an index 
incorporating smoking duration, time since cessation and smoking intensity into a 
single variable [7,8]. The CSI depends on two parameters which are estimated for each 
outcome separately: the half-life, i.e. the rate at which the smoking’s impact decays over 
time, and the lag-time, i.e. the delay between smoking and its impact.  
Never smokers carry a CSI of 0 and higher CSI values indicate more smoking. The CSI 
values are estimated separately for each outcome variable and hence the CSIs including 
their ranges are different for each outcome variable. The results from the CSI regression 
analyses should be interpreted in the following way: The beta values represent the 
additive increase or decrease in the outcome variable per unit increase in the CSI. The 
odds ratio (OR) values represent the increase in odds for the presence of the outcome 
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variable per unit CSI increase. OR values larger than one indicate that increased 
smoking increases the likelihood of occurrence of the outcome. 
Missing data were imputed using multiple imputation with chained equations [9]. The 
regression analyses shown in this paper are all based on imputed data; the results based 
on a complete case analysis are represented in Supplementary Table 6. 
Analyses were performed with Stata/IC15.1 (StataCorp, USA). 
 
RESULTS  
Patient and smoking characteristics 
Of the 12,912 adult SSc patients within EUSTAR, 6179 (48%) patients had no smoking 
data available; in 3414 (26%) patients had no follow-up visit in the required time frame. 
Therefore 3,319 (26%) patients fulfilled the inclusion criteria (Supplementary Figure 
1). The included patients had clinically similar demographic and disease characteristics 
than the excluded patients (Supplementary Table 5). On average, a follow-up visit was 
recorded 1.4 years (SD 0.33) after baseline. Patients were on average 57 years old and 
85% were female. Demographic and disease characteristics are shown in Table 1. 
66% of patients were never smokers, 23% ex-smokers and 11% were current smokers; 
13% of the current smokers (1.5% of patients) stopped smoking during the observation 
time on average 9 months after the baseline visit. The average ex-smokers had smoked 
18 pack-years (SD 21) during a time of 19 years (SD 12) and ceased smoking 15 years 
(SD 13) ago. 49% of the ex-smokers had ceased smoking before RP onset and 58% had 
quit before the onset of the first non-RP manifestation. The average current smoker had 
smoked 27 pack-years (SD 30) during a time of 30 years (SD 13).  
As patients with interstitial lung disease (ILD) might be more likely to cease smoking 
than patients without ILD there might be a higher percentage of ILD patients in the 
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previous smoker group possibly leading to worse trajectories in lung function 
measures. Therefore, in addition to analyzing the entire study population, we also 
analyzed the progression of lung function measures separately for patients with ILD on 
high resolution CT (HRCT) and patients without ILD on HRCT. Among all patients, 49% 
had signs of ILD on HRCT. The smoking behavior patterns were similar in patients with 
ILD and in patients without ILD; 68% of patients in both groups were never smokers, 
23% of patients with and 20% of patients without ILD were previous smokers, and 9% 
of patients with and 12% of patients without ILD were current smokers (p=0.06). 
 
FEV1/FVC ratio 
Never smokers had a significantly higher baseline FEV1/FVC ratio than previous and 
current smokers (Table 1). These differences in baseline FEV1/FVC ratio were seen in 
all three smoking models (Figure 1; Table 2; Supplementary Table 7). As can be seen in 
Table 2, patients had a 2.7 unit lower FEV1/FVC ratio per unit increase in the CSI. 
Medium and heavy smokers had lower baseline FEV1/FVC ratios than never smokers 
and light smokers (all p<0.001; Supplementary Table 7). 
In univariable analysis, the FEV1/FVC ratio declined similarly across smoking groups 
(p=0.065); in multivariable analysis, the FEV1/FVC ratio however declined faster in 
current smokers (Figure 1); this result was also observed when stratifying the study 
population into ILD and non-ILD patients (data not shown). 
 
FVC  
There was no significant difference in baseline FVC and in the FVC change between the 
three smoking groups (Table 1). This lack of a robust effect of smoking on the baseline 
FVC and on the FVC change was also observed in all three multivariable models (Figure 
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1; Table 2; Supplementary Table 7). This lack was also observed when assessing the FVC 
changes separately for ILD and non-ILD patients (data not shown).  
 
DLCO/sb 
Smokers had lower baseline DLCO/sb levels than never smokers (p<0.001; Table 1); 
smoking was associated with low baseline DLCO/sb in all three models (Figure 1; Table 
2; Supplementary Table 7). 
The DLCO/sb declined similarly across all three smoking behavior groups in univariable 
(Table 1) and multivariable analysis (Figure 1; Table 2; Supplementary Table 7), these 
results were also true when looking at ILD and non-ILD patients separately (data not 
shown). 
 
PAPsys 
The average baseline PAPsys was slightly higher in never smokers than in current or ex-
smokers (Table 1). These differences stayed apparent but to a lesser extent not only 
when assessing the smoking groups multivariably, but also evaluating smoking intensity 
and the CSI (Figure 1; Table 2; Supplementary Table 7). 
The PAPsys increased similarly in the groups in univariable (Table 1) and multivariable 
analysis (Figure 1; Table 2; Supplementary Table 7). 
 
Skin involvement 
No association was evident between the severity of skin fibrosis and the smoking 
history regardless of the smoking matrices used (Table 1; Figure 1; Table 2; 
Supplementary Table 7). SSc sine scleroderma, however, was twice as prevalent in 
current as in ex- or never smokers (Table 1). 
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In all smoking models, no clinically significant difference in mRSS evolution was 
observed (Table 1; Figure 1; Table 2; Supplementary Table 7). 
 
DU 
The prevalence of DUs was comparable in the smoking behavior groups (Table 1). 
However, heavy smokers had a greater likelihood of DUs than never smokers in 
multivariable analysis (OR=1.6, p=0.02; Supplementary Table 7); also, a higher CSI was 
associated with the presence of DUs at baseline (OR=1.2, p=0.002, i.e. for a one unit 
increase in CSI, the odds of having DUs at baseline increases by a factor of 1.19; Table 2). 
In the sub-group of DU-naïve patients at baseline, 14% of never smokers developed new 
DUs in between the two visits, compared to 16% ex-smokers and 8% current smokers 
(p=0.05). Ex-smokers had comparable odds than never smokers to develop DU between 
the two visits (OR=1.1, p=0.7); current smokers developed DUs less often than never 
smoking patients (OR=0.5, p=0.031). The smoking intensity was not associated with 
incident DU during the observation period (Supplementary Table 7). 
 
DISCUSSION 
Our study is by far the largest prospectively investigating the effect of smoking on SSc 
outcomes. Smoking was common in our patients, however less than in Anglo-Saxon 
cohorts and also much lower than the European average of around 28% [4,5,10]. 
The EUSTAR cohort replicated the known adverse effect of smoking on bronchial 
airways in terms of a decline in FEV1/FVC and DLCO. Given the absence of discernible 
adverse effects of smoking on PAPsys the effect of smoking on diffusion capacity may 
reflect emphysema rather than precapillary pulmonary vasculopathy. Adverse effects of 
smoking on pulmonary airway obstruction and diffusing capacity were also seen in two 
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cohorts of 137 SSc and 19 smokers [11,12]. In line with one of these cohorts [11] but in 
contrast to the second study [12] we found no association between lung compliance 
(FVC) and smoking status. 
Our study also found no robust effect of smoking on DU prevalence and incidence when 
assessing the smoking behavior itself or assessing the smoking intensity, similar to two 
smaller studies [13,14]. We even found a negative association between tobacco 
exposure and incident DU during the follow-up in a sub-group of DU naïve patients 
(OR=0.5). This effect could not be explained by differences in immunosuppressive and 
vasoactive medication (data not shown). However, when we assessed smoking using the 
CSI we did find an association of smoking on DU prevalence similar to another, however 
quite smaller study also using the CSI [4]. This difference could partially arise due to a 
‘healthy smoker effect’, although this bias is partly been accounted for by the CSI [15]. 
Given these results, it is difficult to draw robust conclusions on the effect of smoking on 
DUs. 
In our study, smokers had a lower prevalence of Scl-70 autoantibodies than previous 
and never smokers. This imbalance in autoantibody status is also in line with that found 
in another study, in which Scl-70 positive patients were more likely to be never smokers 
than ever smokers [2] raising the possibility of a aethiopathological link between 
smoking and Scl-70 positivity. The question, however, is if this imbalance is partly due 
to a link, maybe a causal one, between smoking and autoantibody status or if this 
imbalance is partly explained by a ‘healthy smoker effect’ especially as the prevalence of 
Scl-70 positivity in previous smokers is more comparable to the never smokers than to 
current smokers. 
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Like all registry-based studies the EUSTAR cohort has limitations. We had no means to 
verify the smoking information provided by the patients, however we were able to 
demonstrate known adverse effects of smoking on airway obstruction suggesting that 
the information provided by the patients was not random and that our study was 
powered to detect meaningful changes in other parameters.  
By requiring the study population to have a follow-up visit there is a possibility that we 
excluded sicker patients, i.e. that we introduced a selection bias for healthier patients. 
However, at baseline the patients that were excluded due to the absence of a follow-up 
visit within the required time frame were not majorly worse off than the included 
patients (Supplementary Table 5) arguing against a major selection bias. 
In summary, our study demonstrates an adverse effect of smoking on pulmonary 
airways, but no effects on SSc-specific pulmonary and cutaneous involvement. These 
data argue against a major role of tobacco associated free radicals, vasoconstrictory and 
immunomodulatory effects in the pathogenesis of SSc vasculopathy and fibrosis. 
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Table 1. Baseline demographic and disease characteristics as well as outcome measures 
by smoking status.  
ACA, anticentromere autoantibodies; DLCO/sb, single breath diffusing capacity for 
monoxide; ESR, erythrocyte sedimentation rate; FEV1, forced expiratory volume in one 
second; FVC, forced vital capacity; LVEF, left ventricular ejection fraction; mRSS, 
modified Rodnan skin score; NYHA, New York heart association; PAPsys, systolic  
pulmonary artery pressure as estimated by echocardiography; RNAP-III, anti-RNA 
polymerase-III autoantibodies; RP, Raynaud’s phenomenon; Scl-70, anti-topoisomerase 
autoantibodies.  
*based on the follow-up visit, not the 12 months projection. **The changes in outcomes 
are given downscaled to “per 12 month”. #Number of patients with available 
information for each variable. 
Characteristics of the study 
population 
n# Never 
smokers 
Ex-
smokers 
Current 
smokers 
p-value 
% or  
mean (SD) 
% or  
mean (SD) 
% or  
mean (SD) 
N   2205 752 362  
Age; years 3319 57.5 (14.1) 57.2 (12.1) 52.5 (11.2) <0.001 
Male sex 3319 8 27 29 <0.001 
Disease characteristics        
Time since RP onset; years  3286 14.9 (11.7) 13.4 (11.3) 13.3 (11.8) 0.001 
Time since first non-RP 
manifestation; years 
2988 11.7 (8.8) 10.5 (8.7) 8.9 (7.8) 
<0.001 
Skin 
involvement 
Sine 3106 7 8 15 
<0.001 Limited 64 62 58 
Diffuse 29 30 27 
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mRSS 2949 7.7 (7.4) 7.8 (7.9) 6.9 (7.3) 0.14 
Follow-up mRSS* 2839 7.4 (7.2) 7.2 (7.1) 6.9 (6.9) 0.40 
Change in mRSS** 2684 -0.3 (3.4) -0.6 (4.0) -0.2 (3.3) 0.12 
Esophageal symptoms 3275 60 66 58 0.010 
Stomach symptoms 3241 23 23 21 0.68 
Intestinal symptoms 3250 27 30 29 0.24 
Dyspnea; NYHA 
functional class 
I 3114 57 54 63 
0.001 
II 33 34 31 
III 9 10 5 
IV 1 2 1 
Digital ulcers, current 3125 14 14 16 0.7 
Digital ulcers, ever 3125 46 48 45 0.56 
LVEF; % 2448 62.3 (6.1) 61.7 (6.3) 63.0 (5.8) 0.015 
FEV1/FVC ratio 2256 97.5 (13.5) 95.4 (15.2) 92.8 (15.0) <0.001 
Follow-up FEV1/FVC ratio* 1988 97.1 (12.0) 95.4 (14.5) 90.5 (12.7) <0.001 
Change in FEV1/FVC ratio** 1656 -0.3 (10.1) 0.4 (9.4) -1.6 (7.7) 0.065 
FVC; % of predicted 2720 96.1  (22.0) 96.7 (21.3) 98.3 (19.7) 0.25 
Follow-up FVC*; % of 
predicted 
2435 95.5 (22.8) 96.3 (22.5) 99.3 (18.8) 0.037 
Change in FVC**; % of 
predicted 
2166 -0.6 (8.5) -0.4 (7.7) 0.1 (9.4) 0.45 
DLCO/sb; % of predicted  2583 69.8 (19.6) 66.4 (20.4) 67.1 (17.8) <0.001 
Follow-up DLCO/sb*; % of 
predicted 
2253 67.5 (20.0) 65.6 (20.0) 64.4 (18.1) 0.021 
Change in DLCO/sb**; % of 
predicted 
1977 -2.0 (9.1) -1.7 (9.2) -2.0 (7.8) 0.86 
PAPsys; mmHg 2317 28.8 (16.9) 26.0 (1.0) 24.3 (12.5) <0.001 
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Follow-up PAPsys*; mmHg 2055 29.2 (13.6) 28.5 (14.1) 24.7 (11.6) <0.001 
Change in PAPsys**; mmHg 1706 0.6 (10.5) 1.6 (8.5) 0.2 (8.1) 0.18 
Laboratory parameters      
ACA positive 2508 47 47 61 
<0.001 Scl-70 positive 45 40 31 
RNAP-III positive 3 6 6 
ESR; mm/hr 2795 22.8 (18.4) 18.9 (16.7) 18.0 (14.5) <0.001 
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Table 2. Regression analysis comparing outcomes at baseline and progression of 
outcomes according to the comprehensive smoking index (CSI) adjusted for age, sex, 
time since the onset of Raynaud’s phenomenon, time since the first non-Raynaud’s 
phenomenon manifestation, antibody status and extent of skin involvement. 
The first column illustrates the mean and the range of each outcome’s CSI based on the 
imputed dataset. Higher CSIs indicate more smoking; never smokers carry a CSI of 0.  
The beta values represent the additive increase or decrease in the outcome variable per 
unit increase in the CSI. The OR values represent the increase in odds for the presence 
of the outcome variable per unit CSI increase. OR values larger than one indicate that 
increased smoking increased the likelihood of occurrence of the outcome.  
The follow-up part of the table assesses the projected change per 12 months of the 
outcomes. 
CI, confidence interval; DLCO/sb, single breath diffusing capacity for monoxide; DU, 
digital ulcers; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; 
mRSS, modified Rodnan skin score; OR, odds ratios; PAPsys, systolic pulmonary artery 
pressure as estimated by echocardiography. 
Outcomes  Mean CSI 
(range) 
CSI 
β or OR 95%CI p-value 
Baseline     
FEV1/FVC 0.45 (0-4.09) β= -2.71 -3.46 to -1.97 <0.001 
FVC 0.34 (0-5.12) β= 0.41 -0.39 to 1.22 0.32 
DLCO/sb 0.27 (0-2.94) β= -4.38 -5.89 to -2.88 <0.001 
PAPsys 0.23 (0-2.61) β= -2.08 -3.57 to -0.58 0.006 
mRSS 0.40 (0-7.05) β= 0.20 -0.03 to 0.43 0.088 
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DU current  0.35 (0-7.94) OR= 1.19 1.07 to 1.32 0.002 
Follow-up     
FEV1/FVC 0.33 (0-6.69) β= -0.45 -0.93 to 0.02 0.059 
FVC 0.46 (0-6.36) β= 0.32 -0.01 to 0.66 0.059 
DLCO/SB 0.43 (0-4.02) β= 0.37 -0.16 to 0.90 0.17 
PAPsys 0.35 (0-6.19) β= -0.21 -0.76 to 0.34 0.45 
mRSS 0.43 (0-6.36) β= -0.16 -0.29 to -0.02 0.021 
DU new btw visits  0.30 (0-8.37) OR= 0.83 0.68 to 1.00 0.056 
 
Figure 1.  Regression analysis comparing outcomes by smoking status adjusted for age, 
sex, time since the onset of Raynaud’s phenomenon, time since the first non-Raynaud’s 
phenomenon manifestation, antibody status and extent of skin involvement.  
Panel A shows the multiple adjusted baseline levels of the outcome measures and 
corresponding 95% confidence intervals and panel B shows the multiple adjusted 
change rates in the outcome measures between baseline and the projected 12 months 
follow-up. Light grey represents never smokers, medium grey represents ex-smokers 
and dark grey represents current smokers. 
DLCO/sb, single breath diffusing capacity for monoxide (% of predicted); FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity (% of predicted); mRSS, 
modified Rodnan skin score; PAPsys, systolic pulmonary artery pressure as estimated 
by echocardiography (mmHg). 
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